DEFA14A: Premier to Go Private in $28.25/Share Patient Square Deal

Premier, Inc. announced an agreement to be acquired by Patient Square Capital for $28.25 per share in cash, transitioning to a private company.

Summary

• Premier, Inc. has agreed to be acquired by an affiliate of Patient Square Capital, a dedicated healthcare investment firm, for $28.25 per share in cash.
• The transaction will result in Premier becoming a private company, with its stock no longer listed or traded on NASDAQ or any other public exchange.
• Premier's Board of Directors unanimously determined that this transaction is in the best interests of Premier and its stockholders, delivering immediate and certain value.
• As a private company, Premier will benefit from Patient Square Capital's financial support, gaining access to additional capital and resources.
• This enhanced financial flexibility is expected to accelerate the advancement and tech-enablement of Premier's product portfolio, capitalize on emerging opportunities, and drive innovation.
• The transaction is subject to approval by Premier stockholders and the satisfaction of regulatory approvals and other customary closing conditions.
• Completion of the transaction is expected by the first quarter of calendar year 2026.

Sentiment

Score: 8

Explanation: The announcement of a definitive acquisition at a fixed cash price per share provides immediate and certain value to stockholders, which is a strong positive. The transition to a private company with additional capital and resources for innovation is also positive for the company's future, despite the delisting. Risks are standard for such transactions but are clearly outlined.

Positives

• Stockholders will receive immediate and certain value of $28.25 per share in cash.
• Premier will gain access to additional capital and resources as a private company under Patient Square Capital's ownership.
• Enhanced financial flexibility is expected to accelerate product portfolio advancement and tech-enablement.
• The company will be better positioned to capitalize on emerging opportunities and push innovation in the healthcare industry.
• Patient Square Capital brings deep industry expertise, significant capital, and a strong track record of helping companies reach their full potential.
• Premier's Board of Directors unanimously approved the transaction, indicating strong internal support.

Negatives

• Premier's stock will be delisted from NASDAQ and will no longer trade on public exchanges.
• The proposed transaction may cause disruption, making it more difficult to maintain business and operational relationships.
• There is a risk of significant transaction costs associated with the acquisition.
• Management's attention may be diverted from ongoing business operations due to the proposed transaction.

Risks

• Inability to consummate the proposed transaction within the anticipated time period, or at all, due to failure to obtain required regulatory approvals.
• Failure to satisfy other conditions to the consummation of the proposed transaction, including the approval of Premier's stockholders.
• Risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Premier Class A Common Stock.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and others.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Future Outlook

Premier will transition to a private company, benefiting from Patient Square Capital's financial support to accelerate the advancement and tech-enablement of its product portfolio, capitalize on emerging opportunities, and continue innovation to meet evolving healthcare industry needs. The transaction is expected to close by the first quarter of calendar year 2026.

Management Comments

• "We just announced that we have agreed to be acquired by an affiliate of Patient Square Capital... for $28.25 per share in cash." Mike Alkire, President and CEO.
• "This announcement is the result of our intentional strategy to best position Premier for the long term and benefit all stakeholders." Mike Alkire, President and CEO.
• "Premier's Board of Directors has carefully considered a wide range of strategic alternatives... and unanimously determined that this transaction with Patient Square is in the best interests of Premier and its stockholders." Mike Alkire, President and CEO.
• "As a private company with Patient Square's financial support, Premier will benefit from access to additional capital and resources." Mike Alkire, President and CEO.
• "Patient Square understands our business model and strategy, believes in our team and our mission to improve the health of communities, and shares our commitments to people, integrity, innovation and high performance." Mike Alkire, President and CEO.
• "We expect to complete the transaction by the first quarter of calendar year 2026, subject to approval by Premier stockholders and the satisfaction of regulatory approvals and other customary closing conditions." Mike Alkire, President and CEO.

Industry Context

The acquisition of Premier, a leader in healthcare supply chain expertise, technology, and advisory capabilities, by Patient Square Capital, a dedicated healthcare investment firm, reflects a broader trend of private equity interest in healthcare infrastructure and technology. This move aims to leverage private capital to accelerate innovation and operational efficiencies within the healthcare sector, aligning with the industry's evolving needs for advanced solutions and consolidation.

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Risk of unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Stakeholder Impact

• Stockholders: Will receive immediate and certain value of $28.25 per share in cash upon closing.
• Members/Customers: Premier aims to continue elevating patient care and making healthcare better through the partnership, with enhanced capabilities and innovation.
• Employees: Expected to stay focused on day-to-day priorities; will be part of a private company with enhanced financial flexibility and resources.
• Partners: Expected to benefit from Premier's accelerated advancement and innovation capabilities.
• Suppliers: Business relationships are expected to continue, with potential for enhanced capabilities and strategic alignment.

Next Steps

• Premier stockholders' approval of the transaction.
• Satisfaction of regulatory approvals.
• Satisfaction of other customary closing conditions.
• Completion of the transaction by the first quarter of calendar year 2026.
• Internal leadership briefing at 11:00 AM ET today.
• All-employee town hall at 11:30 AM ET today.
• Continued operation as a public company until closing.
• Preparation and filing of a proxy statement on Schedule 14A with the SEC.

Key Dates

Recommendation

For existing shareholders, the definitive agreement to be acquired at $28.25 per share in cash provides a clear exit strategy. Holding the shares until the transaction closes allows them to receive the agreed-upon cash value, assuming the deal completes as expected and no superior offers emerge. For new investors, any arbitrage opportunity would depend on the current market price relative to the offer price, but the filing primarily confirms the acquisition terms for existing holders.

Keywords

Premier Inc., Patient Square Capital, Acquisition, Take-private, Healthcare, Supply Chain, Advisory Services, Merger, SEC Filing, NASDAQ Delisting